Challenges in the use of NG2 antigen as a marker to predict MLL rearrangements in multi-center studies
Mariana Emerenciano1, Gabriel Renaud, Mariana Sant'Ana
1Pediatric Hematology and Oncology Program, Research Center, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Abstract:
Rearrangements in MLL (MLL-r) are common within very young children with leukemia and affect the prognosis and treatment. Previous studies have suggested the use of the NG2 molecule as a marker for MLL-r but these studies were performed using a small number of infants. We analyzed 148 patients (all less than 24 months, 86 less than 12 months) from various centers in Brazil to determine the predictive power of NG2 within that cohort. We show that NG2 can be used for MLL-r prediction; however, proper staff training and standardized sampling procedures are essential when receiving samples from multiple centers as the accuracy of the prediction varies greatly on a per center basis.
Insights
NG2 molecule shows promise in predicting Mixed Lineage Leukemia rearrangements (MLL-r) in infants. However, multi-center studies require standardized procedures and staff training for accurate MLL-r prediction.
Area of Science:
- Pediatric Oncology
- Hematology
- Molecular Diagnostics
Background:
- Mixed Lineage Leukemia rearrangements (MLL-r) are prevalent in infant leukemia, impacting patient prognosis and treatment strategies.
- The NG2 molecule has been previously investigated as a potential biomarker for MLL-r, but studies were limited by small sample sizes.
- Accurate identification of MLL-r is crucial for tailoring therapeutic approaches in pediatric leukemia.
Purpose of the Study:
- To evaluate the predictive value of the NG2 molecule for MLL-r in a large cohort of Brazilian infants.
- To assess the feasibility and accuracy of NG2 as a diagnostic marker across multiple participating centers.
- To identify factors influencing the reliability of NG2-based MLL-r prediction in a real-world clinical setting.
Main Methods:
- Analysis of 148 pediatric patients under 24 months of age with leukemia from various Brazilian centers.
- Assessment of NG2 molecule expression as a potential predictor of MLL-r.
- Comparative analysis of NG2 prediction accuracy across different participating centers.
Main Results:
- NG2 demonstrates predictive capability for MLL-r in the studied infant cohort.
- Significant variability in prediction accuracy was observed on a per-center basis.
- The reliability of NG2 as a predictive marker is influenced by factors such as staff training and sampling standardization.
Conclusions:
- The NG2 molecule can serve as a useful marker for predicting MLL-r in young children with leukemia.
- Standardized protocols and comprehensive staff training are critical for ensuring consistent and accurate NG2-based MLL-r prediction in multi-center collaborations.
- Further research may refine NG2-based diagnostic strategies for infant leukemia.
